Whole-exome sequencing analysis on products of conception: A cohort study to evaluate clinical utility and genetic etiology for pregnancy loss

INTRODUCTION

The incidence of pregnancy loss from implantation to clinically recognized spontaneous abortions (SAB) was approximately 30%.¹ From a household survey of women aged 15-44 years in the United States during the 1990-2011, self-reported pregnancy loss was noted in approximately 20% of pregnancies with a trend of an increased risk of 1% per year after excluding maternal factors.² Pregnancy loss includes spontaneous abortion (SAB) or miscarriage defined as fetal death prior to 20 weeks of gestation, and stillbirth defined as fetal death at 20 weeks of gestation or greater. Pregnancy loss can have significant physiologic and psychological consequences for women and families. Identify underlying genetic causes could reduce self-blame among those losing a pregnancy and allow for effective clinical management of future pregnancies.³

Genetic abnormalities are known to cause pregnancy loss. Diagnostic karyotyping and microarray analysis identified numerical and structural chromosomal abnormalities and pathogenic copy number variants (pCNVs) in 50% and 4% of products of conception (POC) cases, respectively.⁴ Further analysis of these chromosomal abnormalities and pCNVs identified candidate critical genes and potential interactive gene networks affecting early embryonic development.^4,5 The first report of whole exome sequencing (WES) on a family with recurrent pregnancy loss due to nonimmune hydrops fetalis identified a homozygous rare variant in a highly conserved region of the CHRNA1 gene as a Mendelian cause.⁶ Further application of WES detected relevant alterations in four out of seven cases of fetal demises,⁷ and compound heterozygous mutations in two out of four miscarriages.⁸ More recent WES studies detected positive, possible and candidate variants in 20%, 45% and 9% of 84 fetal death cases with ultrasound anomalies, respectively,⁹ and sequence variants in 15 out of 19 POC cases with missed abortion.¹⁰ Targeted sequencing on a panel of 70 genes associated with cardiac channelophies and cardiomyopathies detected pathogenic variants in 12% of 290 cases of stillbirth.¹¹ Despite the differences in case selection criteria and inconsistency in variant classification from these studies, accumulated research data indicated that exome sequencing may be instrumental in identifying monogenic causes of a significant portion of pregnancy loss cases and should be integrated into the diagnostic practice.

We performed WES on a cohort of POC samples with normal chromosome and microarray findings. The technical feasibility and sensitivity of this assay were evaluated. Variant classification followed current standards and guidelines developed by the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology.¹² Result interpretation was given by disease association and the possibility of prenatal lethality resulting in pregnancy loss. Approaches to integrate WES into current prenatal diagnosis, genetic counseling and reproduction management were proposed.

MATERIALS AND METHODS

Exome sequencing, variant filtering, classification and confirmation

DNA samples obtained from each case in the cohort were subjected to WES at the Yale Center for Genome Analysis. An initial clinical application of WES estimated the sensitivity for detecting heterozygous variants to be 98% with mean 40X sequencing coverage.¹⁴ A pipeline to assess the pathogenicity and causality of detected variants was validated as previously described¹⁵ and adopted for current study. Briefly, paired end sequence reads were converted to FASTQ format and were aligned to the reference human genome assembly GRCh37/hg19 (https://genome.ucsc.edu/). Following variant annotation using a Genome Analysis Toolkit (GATK) and AnnoVar, filtering was applied against allele frequencies and disease citations using databases including Genome Aggregation Database (gnomAD, https://gnomad.broadinstitute.org/), an internal database of Yale DNA Diagnostics Laboratory, ClinVAR (https://www.ncbi.nlm.nih.gov/clinvar/), OMIM (https://www.omim.org) and other in silico attributes. Variants with allele frequency above 3% were excluded from further analysis.

Following ACMG standards and guidelines, the variants with an allele frequency <3% were categorized as pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign and benign variants.¹² For this cohort, an additional criterion of VUS favor pathogenic (VUSfp) was applied by in-house rules to include primarily rare missense variants in a gene with a low rate of benign variants and nearby missense variants reported as disease-causing variants.¹⁶ Additional deleterious effects of these VUSfp were further analyzed by in-silico tools of PolyPhen, SIFT, and CADD. Pathogenic, likely pathogenic and VUSfp were considered variants of diagnostic value. VUSs and benign or likely benign variants were excluded from further analysis. Variants of diagnostic value were verified by Sanger sequencing. Primers flanking the variants for polymerase chain reaction (PCR) are listed in Supplementary Table S1. Purified PCR products were submitted to the Yale DNA sequencing facility for Sanger sequencing. The scheme of variant annotation, filtering and classification is shown in Figure 1.

• Download figure
• Open in new tab

Figure 1. A scheme for variant annotation, filtering and classification.

Variants classified as pathogenic, likely pathogenic and VUSfp were considered diagnostic for pregnancy loss.

RESULTS

Clinical Indications and pathologic findings of the POC cases

Maternal age, gestational age, clinical indications and pathologic findings for these 102 cases were summarized in Supplementary Table S3. The male to female ratio was 49 to 53. The distribution of cases by maternal age groups from age 18-48 years and trimester of pregnancy is shown in Figure 2a and 2b. There were 47 cases of SAB, 45 cases of stillbirth, and 10 cases with unknown gestational age (Figure 2c). Approximately 74% (75/102) of the cases had a maternal age within 26 to 40 years (mean maternal age of 32 years), and 72% (66/92) of the specimens were from the second trimester (mean gestational age of 19 weeks).

• Download figure
• Open in new tab

Figure 2. Clinical demographics for the 102 POC cases.

A) Distribution of cases by maternal age (open bar) and cases with variants of diagnostic value (shade bar), B) Distribution of case by gestational trimesters (open bar) and cases with variant of diagnostic value (shade bar), C) Number of cases in SAB, stillbirth and unknown gestational ages and ADR for overall cases and for cases of SAB and stillbirth. (uk, unknown; ADR, abnormality detection rate; P/LP pathogenic/likely pathogenic; VUSfp, variants of uncertain significance favor pathogenic, NL normal).

DISCUSSION

Clinical WES was first introduced in 2009 and was adopted quickly as a highly effective approach for postnatal and prenatal genetic diagnosis of Mendelian disorders.^14,15,22 A retrospective analysis of WES on 146 fetuses with ultrasound abnormalities demonstrated a diagnostic rate of 32% for Mendelian autosomal dominant and recessive disorders.²² A prospective prenatal exome sequencing analysis of a panel of 1628 genes for developmental disorders on a cohort of 610 fetuses with ultrasound detected structural anomalies showed a diagnostic rate of 12% for variants of pathogenicity and potential clinical usefulness.²⁴ The ADR of this cohort was 22% for pathogenic and likely pathogenic variants, with an additional 14% for VUSfp. This diagnostic yield was comparable to the 12%-32% from prenatal clinical exome sequencing and the 20%-74% from deceased fetuses with ultrasound anomalies.⁹ The ADR of 36% from SAB was slightly more than that of 33% from stillbirth, but the difference was not significant. Combing findings from karyotyping, microarray analysis and WES, the ADR from POC specimens was 50%, 4% and 22%-36% for chromosomal abnormalities, pCNVs and monogenic variants, respectively.⁴ These results indicated that, with the addition of WES, current genetic testing can identify a specific genetic etiology in about three quarters of the pregnancy loss cases. Since WES can also detect aneuploidies and pCNVs except for rare balanced or derived chromosome rearrangements and low-level mosaicisms, WES could replace routine cytogenetic evaluations with karyotype and microarray to detect most genetic abnormalities in pregnancy loss.

The challenge in the interpretation of monogenic genetic contributions to pregnancy loss is to clarify disease association and establish cause-effect relationship for fetal death. Recently, accumulated evidence supported causative genetic variants recurring in essential genes involved in embryonic development, organ development and various functions.^25-28 All the variants of diagnostic value reported in this cohort have a clear association with an OMIM condition. Dominant lethal conditions are poorly understood in humans. In this study, approximately 67% of the variants of diagnostic value were identified in an AD condition. Actually, two AD conditions were noted in case PL029 with one VUSfp each in the MIB1 and SHOC2 genes and case PL090 with one VUSfp each in the CSRP3 and NIPBL genes. Similarly, case PL037 had one homozygous VUSfp in the TTC21B which is a recessive ciliopathy gene and a VUSfp variant in the SOS1 gene for a dominant RASopathy. It is possible that the variants in both genes act synergistically to result in fetal death. Of the eight cases associated with AR conditions, homozygous pathogenic variants or VUSfps in the SMPD1, ATP7B, HACE1, TTC21B and COQ2 genes were detected in five cases. While adverse effect on fetal development is more apparent in four genes, ATP7B associated Wilson disease as the cause of fetal death will require further evidence. These cases suggested a possible founder effect in the local testing population. Heterozygous variants of likely pathogenic and VUS were detected in the NPHS1, KIAA1109 and NEB genes associated with a AR condition in three cases. Follow up parental study to determine the phase of these variants and functional analysis on gene expression will be necessary to assess their association to fetal death. A very rare VUSfp in the IDS gene associated with X-linked Mucopolysaccharidosis II was identified in a male SAB case; its pathogenicity of glycosaminoglycan accumulation in CNS and other organ systems for fetal death would need further investigation on fetal autopsy. Some of the variants reported are in genes associated with adult onset diseases, such as FBN1, PKD1 and SMAD6. A variant in the FBN1 gene and a 41-kb deletion containing the TSC2 and PKD1 genes have been reported in fetuses with ultrasound detected abnormality.^22,24 These findings raise the possibility that adult onset conditions associated with these genes may have a broader phenotype than we recognized, and could affect fetal development. Likewise, identifying pathogenic variants in genes known to be associated with neurodevelopmental disorders, such as the AUTS2, FOXP2, SETD5 and SYNGAP1 genes, raises a similar possibility of a broader impact of these genes on fetal development. The results from this cohort illustrated that detailed clinicopathologic investigation is needed to determine the cause of fetal death.

Recurrence of certain disease categories and related genes and variants are considered clinical evidence supporting causal effect for pregnancy loss. In this cohort, disease categories showed considerable overlap with those recognized in prior studies including multisystem disorders, cardiovascular abnormalities, urinary system abnormalities, skeletal dysplasia, and central nervous system abnormalities.^9,11,22-24 Approximately 47% of the cases in this cohort had evidence supporting the identification of a genetic cause for fetal death from previous studies. Of the 15 recurrent genes, most are associated with multisystem disorders, including the CHD7, FBN1, FGFR3, NIPBL and SOS1 genes; and the second most common ones are associated with cardiac anomalies or arrhythmia including the CSRP3, GATA4, GPD1L and SCN5A genes. The other genes are associated with skeletal dysplasia (COL1A1, FGFR2 and FGFR3), kidney diseases (GREB1L and NPHS1) and CNS abnormality (PIK3R2). More specifically, the variant identified in the PIK3R2 gene, p.(Gly373Arg), is identical to the previously reported PIK3R2 variant,²³ and a variant causing Thanatophoric dysplasia, p.(Arg248Cys) in the FGFR3 gene, was previously reported in a case of fetal demise.²⁴ Variants affecting the same amino acid Ile124 were identified in the GPD1L gene.¹¹ Such recurrence at the variant level further supports the important function of certain amino acid positions and protein structure, and that genetic abnormalities at these positions likely contributed to fetal death. The fact that there are recurrent disease categories, genes, and variants found in different studies supports the presence of shared mechanisms and monogenic contributions to pregnancy loss. These results also highlighted that although the genetic etiology underlying pregnancy loss appears to be diverse and heterogenous, some genes may play more critical roles for normal fetal development than others, and fetal development cannot be sustained once these essential genes are deregulated.

There were a few limitations in this study and thus approaches overcoming these limitations should be implemented for clinical use and further research. First, this cohort of 102 cases was adequate to validate the clinical utility of WES but the sample size was insufficient to have a comprehensive evaluation of genetic etiology for pregnancy loss. Given the heterogeneity of disease categories presented in this cohort and other studies, collaborative studies on a large case series will be needed to investigate the monogenic etiology of fetal death. Second, the samples used for this study were de-identified and follow-up parental study was not pursued. Reanalysis of phase and parental origin of variants could be performed following current ACMG recommendations.²⁹ A more complete fetal clinical evaluation combined with a trio study design or a study with follow up parental testing would allow for better assessment of the causality of the variants. Trio analysis has been shown to improve diagnostic yield and variant interpretation over singleton study.⁹ Finally, this study only focused on OMIM genes and was not designed to evaluate non-OMIM genes that might be important for fetal growth and development. Trio study will be critical for discovery of new genes important to fetal development. Furthermore, studies using cellular and animal models should be an integral component of future study design to clarify the functional impact of the identified variants, especially the recurrent and novel variants, on fetal death.

In conclusion, this study demonstrated that 22%-35% of pregnancy losses have variants of diagnostic value in genes that may contribute to fetal death, supporting the use of WES as a valuable genetic testing tool in identifying a cause for pregnancy loss. Identification of recurrent genes and variants associated with fetal death may lead to better understanding of the functions of known OMIM genes in fetal development and their roles in pregnancy loss. Identification of variants of diagnostic value provides necessary information for recurrence risk assessment, follow up parental studies, prenatal genetic counseling, and management of subsequent pregnancies.

SUPPLEMENTARY MATERIALS

The online version of this article contains supplementary figure S1 and supplementary tables S1, S2 and S3.

DISCLOSURE

All authors read and approved the manuscript and declare that they have no conflict of interest.